Reference

1. Türk C, N. A. EAU Guidelines on Urolithiasis. European Association of Urolog. 2021. 
2. Abrams P, et al. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Pharmacother. 2011;12(17):2739-2748. 
3. Chang DF, Chen J. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664-673. 
4. Dellabella M, et al. Silodosin facilitates the passage of distal ureteral stones. Urology. 2010 Mar;75(3):485-9. 
5. Fovargue D, et al. Silodosin: a new alpha-blocker for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2010;67(13):1079-1085. 
6. Furyk JS, et al. Distal Ureteric Stones and Tamsulosin: A Double-Blind, PlaceboControlled, Randomized, Multicenter Trial. Ann Emerg Med. 2016;67(1):86-95.e2. 
7. Fwu CW, et al. Emergency Department Visits, Use of Imaging, and Drugs for Urolithiasis Have Increased in the United States. Kidney Int. 2013;83(3):479-486. 
8. Gacci M, et al. Meta-analysis of the efficacy and safety of silodosin in the treatment of male lower urinary tract symptoms. Urology. 2012;79(6):1290-1297. 
9. Goldfarb DS, et al. Medical Management of Kidney Stones: AUA Guideline. J Urol. 2014;192(2):316-324. 
10. Hänseler E, et al. Clinical pharmacokinetics of silodosin. Clin Pharmacokinet. 2012;51(6):391-403. 
11. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev. 2015;(7):CD004137. 
12. Hollingsworth JM, Canales BK. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016;355:i6112. 
13. J MC. Change in epidemiologic features of urolithiasis in the United States over the last three decades: a population-based study. J Urol. 2011;186(5):1772-1776. 
14. Lepor H, et al. Tamsulosin: preclinical evidence for selectivity to the human seminal vesicles. J Urol. 1997;157(3):1191-1194. 
15. MC M. Pharmacology and clinical use of silodosin for the treatment of benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):483.
16. McVary KT, et al. Silodosin in men with signs and symptoms of benign prostatic hyperplasia: results of a phase III, placebo-controlled, multicenter trial. Urology. 2007;70(6):1111-1116. 
17. Moore CL, et al. Imaging in Suspected Renal Colic: Systematic Review of the Literature and Multispecialty Consensus. Ann Emerg Med. 2019;74(3):391-402. 
18. Pearle MS, et al. Medical management of kidney stones: AUA guideline. American Urological Association. 2014. 
19. Porpiglia F, et al. Silodosin for medical expulsive therapy in ureteral calculi: randomized, double-blind, placebo-controlled study. Urology. 2010;75(6):1275-1280.
20. Preminger GM, et al. Guideline for the management of ureteral calculi. Eur Urol. 2007;52(6):1610-1631. 
21. Roehrborn CG, et al. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2002;59(4):428-433. 
22. Roehrborn CG, van Kerrebroeck P. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92(3):257-261. 
23. Romero V, et al. Kidney stones: A global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2-3):e86-e96. 
24. Salem EA, et al. Tamsulosin hydrochloride: pharmacokinetics and pharmacodynamics in patients with normal and impaired renal function. J Urol. 1999;161(5):1598-1602. 
25. Scales CD Jr, et al. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160-165. 
26. Seitz C, et al. Medical expulsive therapy of ureteral colic with silodosin: a randomized controlled study. World J Urol. 2013;31(6):1565-1570. 
27. Smith-Bindman R, et al. Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med. 2014;371(12):1100-1110. 
28. Stamatelou KK, Francis ME. Time trends in the reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63(5):1817-1823.
29. Takasu T, et al. Silodosin: a selective alpha1A-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2009;10(16):2619-2631. 
30. Tanaka ST, et al. Evaluation and management of pediatric urolithiasis: AUA guideline. J Urol. 2021;206(4):970-978. 
31. Türk C, K. T. Guidelines on Urolithiasis. European Association of Urology. 2020.
32. Türk C, N. A. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol. 2021;80(6):704-718.
33. Xiong T, et al. Efficacy of silodosin in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis. Urolithiasis. 2017;45(5):507-515. 
34. Yamaguchi O, et al. Silodosin in the treatment of lower urinary tract symptoms. Expert Opin Pharmacother. 2012;13(17):2529-2537. 
35. Yan H, Zhu G. Epidemiology and management of urinary stones in pregnant women: a literature review. Urolithiasis. 2018;46(6):553-5